Last reviewed · How we verify
Transoddi (CINAMETIC ACID)
Transoddi (generic name: CINAMETIC ACID) is a drug. It is currently in Phase 2 development.
Transoddi is thought to work by interacting with specific biological pathways, but the exact mechanism is unknown.
Transoddi, also known as Cinamic Acid, is a small molecule drug with unknown target and drug class. Its commercial status is unclear, and it has not been approved by the FDA for any indications. As a small molecule, it is likely to work by interacting with specific biological pathways, but the exact mechanism is unknown. Further research is needed to determine its safety and efficacy. The lack of information on its pharmacokinetics and pharmacodynamics makes it difficult to assess its potential as a therapeutic agent.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | CINAMETIC ACID |
|---|---|
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | Phase 2 |
Mechanism of action
Imagine your body's cells are like a complex orchestra, with many different instruments working together to create a beautiful symphony. Transoddi is like a new instrument that is being introduced into the orchestra, but we don't know exactly how it will fit in or what it will sound like. As it interacts with the other instruments, it may help to create a more harmonious and balanced sound, but we need more research to understand how it works.
Approved indications
Common side effects
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Transoddi CI brief — competitive landscape report
- Transoddi updates RSS · CI watch RSS
Frequently asked questions about Transoddi
What is Transoddi?
How does Transoddi work?
What is the generic name of Transoddi?
What development phase is Transoddi in?
Related
- Therapeutic area: All drugs in Other
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing